The Moross Integrated Cancer Center (MICC) was established by Weizmann Institute of Science in order to address the immense challenges posed by cancer - one of the most common and deadly diseases worldwide. By combining basic and clinical research with cutting-edge technologies and collaborations between scientists and medical oncologists the MICC is becoming a powerful hub for inspiring, enabling, and stimulating groundbreaking research to facilitate the battle against cancer.

The MICC has a solid basic research component comprised of the Swiss Society Institute for Cancer Prevention Research, headed by Prof. Zvi Livneh, the EKARD Institute for Cancer Diagnosis Research, headed by Prof. Yardena Samuels, and the Dwek Institute for Cancer Therapy Research, headed by Prof. Yosef Yarden.

The second component of the MICC focuses on the infrastructure: Weizmann-Brazil Tumor Bank, headed by Prof. Yardena Samuels, the Kleinman Cancer Cell Sorting Facility, headed by Prof. Steffen Jung , and the de Picciotto Cancer Cell Observatory In Memory of Wolfgang and Ruth Lesser, headed by Prof. Benjamin Geiger.


Prof. Moshe Oren has contributed significant insights to understanding p53, the tumor suppressor gene that is a key player in molecular cancer control. His findings have enabled physicians to develop innovative therapeutic strategies, including the first clinically approved anti-cancer gene therapy. Prof. Oren’s current work deals with understanding the mechanisms that govern the activity of p53 in normal and in cancer cells.